Based on these data, a potential mechanism through which HMGB1 promotes anti-PD-1/PD-L1 therapy-mediated anticancer immunity might be explained as follows; in general, cancer immunity cycle, which involves several important steps, is proposed to explain the mechanism of action of ICIs [14]. Here, HMGB1 is linked to cancer.